NewLink Genetics Announces Final Results from Phase 2 Studies of Indoximod in Advanced Melanoma and Metastatic Pancreatic Cancer ...
AMES, Iowa, May 16, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that abstracts from two Phase 2 studies of indoximod, used in combination with other agents, are now available on the website of the 2018 American …